Vinodh Mechery

Vinodh Mechery

Auto-generated profile, based on publicly available information

Vinodh Mechery

Department of Medicine, University of Miami Miller School of Medicine

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2019 in JMIR Human Factors
Verified
Journal Article
Open access
SKSundas Khan
Sundas Khan
SRSafiya Richardson
Safiya Richardson
ALAndrew Liu
Andrew Liu
VMVinodh Mechery
Vinodh Mechery
LMLauren McCullagh
Lauren McCullagh
TMThomas McGinn
Thomas McGinn
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Successful clinical decision support (CDS) tools can bring evidence-based medicine to the point-of-care to effectively improve patient outcomes. However, the impact of these tools has been limited by low provider adoption due to over-triggering, leading to alert fatigue. We have developed a tracking mechanism for monitoring trigger rate (percent of total visits for which the tool triggers) and adoption rate (percent of completed tools) of a complex CDS tool based on the Wells’ Criteria for pulmonary embolism (PE). Objective: Monitor and evaluate the adoption and trigger rates of the tool and to see if ongoing tool modifications would improve adoption rates. Methods: As part of a larger clinical trial, a CDS tool was developed using the Wells’ Criteria to calculate pre-test probability for PE at two academic tertiary center’s emergency departments (ED). The tool had multiple triggers: any order for D-dimer, computed tomography (CT) of the chest with intravenous contrast, computed tomography pulmonary angiography (CTPA), ventilation/perfusion scan, or lower extremity Doppler ultrasound. A tracking dashboard was developed using Tableau® to monitor trigger and adoption rates in real-time. Based on initial low provider adoption rates of the tool, small focus groups were conducted with key ED providers to elicit barriers to tool use. Over-triggering of the tool for non-PE-related evaluations and inability to order CT testing for intermediate risk patients were identified. Thus, the tool was modified to allow CT testing for intermediate risk group and to not trigger for CT chest with intravenous contrast orders. Additionally, a dialogue box, “Are you considering PE for this patient?” was added before the tool triggered to account for CTPAs ordered for the evaluation of aortic dissection. Results: In the first academic tertiary center’s ED, 95,295 patients were seen during the academic year. The tool triggered for an average of 509 patients per month (6.73%) before the modifications and this reduced to 423 patients per month (5.22%). The second academic tertiary center’s ED saw 88,956 patients during the academic year with the tool triggering for about 473 patients per month (6.38%) before the modifications, and for about 400 (5.12%) afterwards. The modifications resulted in a significant 4.5-fold and 3-fold increase in provider adoption rates. The modifications increased the average monthly adoption rate from 6.51% to 29.33% in center 1, and also increased from 14.73% to 42.64% in center 2. Conclusions: Close post-implementation monitoring of CDS tools may help to improve provider adoption. Adaptive modifications based on user feedback may lead to more targeted CDS with lower trigger rates, reducing alert fatigue and increasing provider adoption. This study provides an example of how iterative improvements and a post-implementation monitoring dashboard resulted in significantly improved adoption rates.

5 March 2018 in JMIR Preprints
Verified
Preprint
Open access
SKSundas Khan
Sundas Khan
SRSafiya Richardson
Safiya Richardson
ALAndrew Liu
Andrew Liu
VMVinodh Mechery
Vinodh Mechery
LMLauren McCullagh
Lauren McCullagh
TMThomas McGinn
Thomas McGinn
BACKGROUND Successful clinical decision support (CDS) tools can help use evidence-based medicine to effectively improve patient outcomes. However, the impact of these tools has been limited by low provider adoption due to overtriggering, leading to alert fatigue. We developed a tracking mechanism for monitoring trigger (percent of total visits for which the tool triggers) and adoption (percent of completed tools) rates of a complex CDS tool based on the Wells criteria for pulmonary embolism (PE). OBJECTIVE We aimed to monitor and evaluate the adoption and trigger rates of the tool and assess whether ongoing tool modifications would improve adoption rates. METHODS As part of a larger clinical trial, a CDS tool was developed using the Wells criteria to calculate pretest probability for PE at 2 tertiary centers’ emergency departments (EDs). The tool had multiple triggers: any order for D-dimer, computed tomography (CT) of the chest with intravenous contrast, CT pulmonary angiography (CTPA), ventilation-perfusion scan, or lower extremity Doppler ultrasound. A tracking dashboard was developed using Tableau to monitor real-time trigger and adoption rates. Based on initial low provider adoption rates of the tool, we conducted small focus groups with key ED providers to elicit barriers to tool use. We identified overtriggering of the tool for non-PE-related evaluations and inability to order CT testing for intermediate-risk patients. Thus, the tool was modified to allow CT testing for the intermediate-risk group and not to trigger for CT chest with intravenous contrast orders. A dialogue box, “Are you considering PE for this patient?” was added before the tool triggered to account for CTPAs ordered for aortic dissection evaluation. RESULTS In the ED of tertiary center 1, 95,295 patients visited during the academic year. The tool triggered for an average of 509 patients per month (average trigger rate 2036/30,234, 6.73%) before the modifications, reducing to 423 patients per month (average trigger rate 1629/31,361, 5.22%). In the ED of tertiary center 2, 88,956 patients visited during the academic year, with the tool triggering for about 473 patients per month (average trigger rate 1892/29,706, 6.37%) before the modifications and for about 400 per month (average trigger rate 1534/30,006, 5.12%) afterward. The modifications resulted in a significant 4.5- and 3-fold increase in provider adoption rates in tertiary centers 1 and 2, respectively. The modifications increased the average monthly adoption rate from 23.20/360 (6.5%) tools to 81.60/280.20 (29.3%) tools and 46.60/318.80 (14.7%) tools to 111.20/263.40 (42.6%) tools in centers 1 and 2, respectively. CONCLUSIONS Close postimplementation monitoring of CDS tools may help improve provider adoption. Adaptive modifications based on user feedback may increase targeted CDS with lower trigger rates, reducing alert fatigue and increasing provider adoption. Iterative improvements and a postimplementation monitoring dashboard can significantly improve adoption rates.

5 August 2026 in Lupus
Verified
Journal Article
Open access
GCGabriel Contreras
Gabriel Contreras
VMVinodh Mechery
Vinodh Mechery
SKSanjana Kota
Sanjana Kota
DRDaniel Del Castillo Rix
Daniel Del Castillo Rix
MBMiguel Bandes
Miguel Bandes
JMJair Munoz Mendoza
Jair Munoz Mendoza
Background: In patients with active lupus nephritis (LN), 8 different triple immunosuppressive therapies have been compared to the standard of care (SOC) of double immunosuppressive therapy in 12 induction randomized clinical trials (RCTs). The triple immunosuppressive therapies of SOC+Tacrolimus, SOC+Voclosporin, SOC+Belimumab, and SOC+Obinutuzumab compared to SOC alone demonstrated significantly higher remission of LN without excessive risk of serious adverse events (SAEs) and serious infectious events (SIEs) in RCTs. Direct or indirect comparisons among triple immunosuppressive therapies have not been studied. In this network meta-analysis (NMA), we systematically provide indirect comparisons of the relative efficacy and safety of triple immunosuppressive therapies, ranking them according to efficacy achieving primary renal remission (PRR) of LN and safety reducing the risk of SAEs and SIEs. Results: The NMA included predominantly women with LN. In direct pairwise comparisons, SOC+Tacrolimus (benefit ratio 1.91 [95% Credible Interval 1.45 to 2.56]), SOC+Voclosporin (1.69 [1.30 to 2.23]), SOC+Obinutuzumab (1.41 [1.09 to 1.84]), and SOC+Belimumab (1.32 [1.04 to 1.69]) had significantly higher PRR compared to SOC alone. In indirect pairwise comparisons, patients who received SOC+Tacrolimus compared to SOC+Rituximab (2.30 [1.27 to 4.20]), SOC+Anifrolumab (1.98 [1.07 to 3.52]), SOC+Ocrelizumab (1.81 [1.12 to 2.82]), and SOC+Abatacept (1.78 [1.07 to 2.91]) had significantly higher PRR. Patients who received SOC+Voclosporin compared to SOC+Rituximab (2.03 [1.14 to 2.68]) had significantly higher PRR. SOC+Belimumab, SOC+Obinutuzumab, SOC+Voclosporin and SOC+Tacrolimus ranked as effective therapies inducing PRR with SUCRA probability scores between 61.14% and 95.12%. Risk ratios of SAE and SIE were not significantly different among the immunosuppressive therapies. Conclusion: In patients with LN, induction therapies of SOC with calcineurin inhibitors had the highest relative benefit achieving remission of LN.